Novo Nordisk's Oral Wegovy Pill Wins EU-Wide Approval

What Did the European Commission Approve on 15 July 2026?

On 15 July 2026, the European Commission granted marketing authorisation for a new oral tablet formulation of Novo Nordisk's Wegovy (semaglutide), available in 1.5mg, 4mg, 9mg and 25mg strengths, for weight management in adults with obesity or with overweight plus at least one weight-related comorbidity.[1] A higher-dose 7.2mg single-dose, ready-to-use injection pen was cleared on the same day.[1] Novo Nordisk describes the tablet as the first oral GLP-1 receptor agonist authorised EU-wide for weight management.[1]

The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on 21 May 2026, which recommended the new oral pharmaceutical form and route of administration as a variation to Wegovy's existing marketing authorisation.[2] Under standard EU procedure, the European Commission's decision extends automatically across all EU member states, rather than requiring separate national sign-off.

What Clinical Data Supported the Approval?

The approved EU label additionally incorporates cardiovascular outcome data from SELECT, the large outcomes trial of injectable semaglutide, which found a reduction in major adverse cardiovascular events among people with pre-existing cardiovascular disease and overweight or obesity.[2] Novo Nordisk has not disclosed a dedicated cardiovascular outcomes trial for the oral 25mg formulation itself; the label draws on the injectable-formulation dataset, a distinction researchers evaluating the regulatory record should note.

How Does This Change the Oral GLP-1 Competitive Landscape?

It hands Novo Nordisk first-mover advantage in the EU oral obesity-pill market. Eli Lilly's rival oral candidate, orforglipron (branded Foundayo), was approved by the US FDA on 1 April 2026 and has been available through US pharmacies and LillyDirect since early April.[4] As of this EU authorisation, Lilly has not secured equivalent European Commission clearance for orforglipron, leaving Novo Nordisk as the only EU-approved oral GLP-1 option for weight management for the time being.[5]

The two molecules differ mechanistically as well as regulatorily: semaglutide is a peptide requiring a permeation enhancer (SNAC) and strict fasting-administration rules to achieve oral bioavailability, while orforglipron is a non-peptide small molecule that Lilly has positioned as easier to manufacture at scale and administer without food or water restrictions.[4] Our coverage of AstraZeneca's elecoglipron covers a third oral GLP-1 candidate still in Phase 2, underscoring how crowded the oral-pill segment of the GLP-1 class has become in 2026 even as retatrutide's injectable triple-agonist programme runs on a separate track.

Does the EU Approval Change Anything for UK Researchers?

No. The UK's medicines-licensing framework has operated independently of the EMA since Brexit, and the MHRA had already granted its own UK approval for an oral semaglutide tablet on 11 June 2026 — over a month before this EU authorisation, and via a wholly separate assessment.[6] See our MHRA oral semaglutide approval guide for that UK-specific decision and the OASIS trial data behind it. The two approvals simply run on parallel regulatory tracks and neither changes the other.

Neither decision has any bearing on UK research-reagent supply. Branded-medicine licensing by the EMA or MHRA governs prescription-only pharmaceutical products; it does not alter the Human Medicines Regulations 2012 framework under which unlicensed compounds are lawfully supplied for in vitro research use.

What Does This Mean for Retatrutide and Injectable GLP-1/GIP Research?

Not much directly. Retatrutide remains an investigational, injectable triple GIP/GLP-1/glucagon receptor agonist, studied exclusively as a once-weekly subcutaneous formulation across Eli Lilly's TRIUMPH Phase 3 programme; no oral retatrutide formulation has been disclosed by Lilly. The oral-pill race described above concerns single-target GLP-1 molecules — semaglutide and orforglipron — that are already licensed medicines, an entirely separate regulatory and mechanistic track from retatrutide's unlicensed, investigational, multi-receptor research profile. Our retatrutide vs. tirzepatide vs. semaglutide comparison lays out the mechanistic distinctions researchers most often ask about between these compound classes.

What this news does confirm is the pace of commercial and regulatory activity across the wider GLP-1 receptor-agonist class in mid-2026: two branded oral pills now hold licences in at least one major market, a third is in Phase 2, and Lilly's own injectable triple-agonist candidate is still working through its TRIUMPH readouts ahead of a targeted Q4 2026 NDA filing, as covered in our retatrutide FDA approval timeline. For UK researchers, retatrutide's regulatory status is unaffected: it remains an unlicensed, investigational compound with no MHRA or EMA marketing authorisation of any kind.

Velox Peptides does not stock semaglutide or orforglipron. This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions